New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
10:56 EDTNRG, BSXStocks with call strike movement; NRG BSX
NRG Energy (NRG) January 35 call option implied volatility decreased 2% to 24, NRG Energy Boston Scientific (BSX) January 15 call option implied volatility decreased 2% to 25 according to IVolatility.
News For NRG;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2014
08:03 EDTNRGNRG Energy acquires Pure Energies
Subscribe for More Information
October 1, 2014
10:00 EDTNRGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Allergan (AGN) upgraded to Buy from Hold at Stifel... Angie's List (ANGI) upgraded to Market Perform from Underperform at Northland... DeVry (DV) upgraded to Buy from Hold at Deutsche Bank... Dynegy (DYN) upgraded to Buy from Hold at ISI Group... Exelon (EXC) upgraded to Buy from Hold at ISI Group... Fluor (FLR) upgraded to Buy from Neutral at DA Davidson... Genworth (GNW) upgraded to Outperform from Neutral at Macquarie... Hecla Mining (HL) upgraded to Buy from Hold at BB&T... InvenSense (INVN) upgraded to Strong Buy from Buy at Needham... Janus Capital (JNS) upgraded to Buy from Hold at Jefferies... Masco (MAS) upgraded to Overweight from Neutral at JPMorgan... NRG Energy (NRG) upgraded to Strong Buy from Buy at ISI Group... Orbitz (OWW) upgraded to Outperform from Perform at Oppenheimer... Panera Bread (PNRA) upgraded to Buy from Hold at Wunderlich... Suncor (SU) upgraded to Buy from Neutral at Citigroup... Susquehanna (SUSQ) upgraded to Outperform from Neutral at Boenning & Scattergood... TPG Specialty Lending (TSLX) upgraded to Outperform from Market Perform at Wells Fargo... Tyson Foods (TSN) upgraded to Neutral from Underperform at Credit Suisse.
08:33 EDTNRGNRG Energy upgraded to Strong Buy from Buy at ISI Group
ISI Group upgraded NRG Energy to Strong Buy based on higher EBITDA forecasts, leverage to long-term capacity pricing, and increased confidence in Gulf Coast natural gas prices. Price target raised to $40 from $34.
September 30, 2014
16:16 EDTNRGDynegy, Exelon, NRG Energy upgraded at ISI Group
ISI Group said capacity market improvements could overcome gas basis concerns for the independent power producers it covers. The firm raised its ratings on Dynegy (DYN) and Exelon (EXC) to Buy, upped its rating on NRG Energy (NRG) to Strong Buy and reiterated its Buy rating on PPL Corp. (PPL). ISI kept a $34 price target on Dynegy, kept a $36 target on PPL Corp., raised its price target Exelon to $39 from $33 and hiked its target NRG to $40 from $34.
16:08 EDTNRGNRG Energy upgraded to Strong Buy from Buy at ISI Group
Subscribe for More Information
10:02 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:56 EDTBSXBoston Scientific initiated with a Hold at Needham
September 24, 2014
16:41 EDTBSXCourt says Boston Scientific breached license agreement
Boston Scientific disclosed in a regulatory filing that on September 24, following a jury verdict against Boston Scientific Corporation, the Montgomery County Circuit Court in Maryland entered a judgment that the company breached its license agreement with Mirowski Family Ventures and awarded damages of $308M. The company believes the facts and the law do not support the jury’s findings or the amount of the damages. The company plans to seek to overturn the judgment in post-trial motions with the Circuit Court and, if necessary, through the appeals process.
September 23, 2014
16:09 EDTBSXBoston Scientific enrolls first patients in U.S. trial of Lotus Valve System
Boston Scientific has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is the first transcatheter aortic valve replacement device that is both fully repositionable and retrievable prior to release. The primary endpoints of the study are Safety; composite of all-cause mortality, stroke, life-threatening and major bleeding events, stage two or three acute kidney injury or major vascular complications at 30 days. Efficacy; composite of all-cause mortality, disabling stroke or moderate or greater paravalvular aortic regurgitation at one year following procedure.
11:03 EDTNRGNRG Energy management to meet with Wolfe Research
Subscribe for More Information
08:15 EDTNRGNRG Energy resumed with a Buy at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use